H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 110 Citations 42,048 661 World Ranking 2444 National Ranking 93

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

His primary areas of investigation include Internal medicine, Transplantation, Surgery, Immunology and Multiple myeloma. His Internal medicine research incorporates elements of Gastroenterology and Oncology. He is interested in Hematopoietic stem cell transplantation, which is a field of Transplantation.

His study in Surgery is interdisciplinary in nature, drawing from both Tolerability, Dexamethasone and Hazard ratio. Much of his study explores Immunology relationship to Virology. The various areas that he examines in his Multiple myeloma study include Adverse effect, Immunopathology and Clinical trial.

His most cited work include:

  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. (1101 citations)
  • Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody (895 citations)
  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (818 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Immunology, Transplantation and Oncology. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. Immunotherapy is closely connected to Cancer research in his research, which is encompassed under the umbrella topic of Multiple myeloma.

His is involved in several facets of Immunology study, as is seen by his studies on Immune system, T cell, Antigen, Aspergillus fumigatus and CD8. Hematopoietic stem cell transplantation is the focus of his Transplantation research. His work in Oncology covers topics such as Myeloid leukemia which are related to areas like Leukemia.

He most often published in these fields:

  • Internal medicine (41.73%)
  • Multiple myeloma (30.46%)
  • Immunology (29.98%)

What were the highlights of his more recent work (between 2017-2021)?

  • Multiple myeloma (30.46%)
  • Internal medicine (41.73%)
  • Oncology (19.90%)

In recent papers he was focusing on the following fields of study:

Hermann Einsele mostly deals with Multiple myeloma, Internal medicine, Oncology, Cancer research and Transplantation. His work focuses on many connections between Multiple myeloma and other disciplines, such as Clinical trial, that overlap with his field of interest in Intensive care medicine. His Hematology, Dexamethasone, Myeloid leukemia and Hematopoietic stem cell transplantation study in the realm of Internal medicine interacts with subjects such as In patient.

Hermann Einsele combines subjects such as Refractory, Elotuzumab, Monoclonal antibody, Daratumumab and Refractory Multiple Myeloma with his study of Oncology. His Cancer research research includes themes of Cell culture, Point mutation, Antigen, Leukemia and Immunotherapy. His work deals with themes such as Stem cell and Immunology, which intersect with Transplantation.

Between 2017 and 2021, his most popular works were:

  • The landscape of genomic alterations across childhood cancers (449 citations)
  • Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (149 citations)
  • A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (125 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Hermann Einsele mainly investigates Multiple myeloma, Internal medicine, Oncology, Transplantation and Cancer research. Hermann Einsele interconnects Hematology, Clinical trial, Disease and Adverse effect in the investigation of issues within Multiple myeloma. His Lenalidomide, Dexamethasone, Hazard ratio and Hematopoietic stem cell transplantation study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.

His Oncology research integrates issues from Young adult, Blinatumomab, Monoclonal antibody and Lymphoma. Hermann Einsele has researched Transplantation in several fields, including Treatment options, Stem cell and Fdg pet ct. His Cancer research research is multidisciplinary, incorporating perspectives in Point mutation, Downregulation and upregulation, CXCR4 and Immunotherapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress.
Biology of Blood and Marrow Transplantation (2009)

1776 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1148 Citations

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)

1097 Citations

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger.
Science (2008)

1033 Citations

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger.
Blood (2002)

891 Citations

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac.
Lancet Oncology (2014)

823 Citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann.
Journal of Clinical Oncology (2006)

794 Citations

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)

720 Citations

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck.
Blood (2006)

622 Citations

The landscape of genomic alterations across childhood cancers

Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter.
Nature (2018)

543 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hermann Einsele

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 147

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 147

Mohamad Mohty

Mohamad Mohty

Université Paris Cité

Publications: 147

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 145

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 135

Nicolaus Kröger

Nicolaus Kröger

Universität Hamburg

Publications: 133

Arnon Nagler

Arnon Nagler

Sheba Medical Center

Publications: 133

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 122

Michael Boeckh

Michael Boeckh

Fred Hutchinson Cancer Research Center

Publications: 117

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 113

Sergio Giralt

Sergio Giralt

Memorial Sloan Kettering Cancer Center

Publications: 108

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 104

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 102

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 100

Sagar Lonial

Sagar Lonial

Emory University

Publications: 99

Michele Cavo

Michele Cavo

University of Bologna

Publications: 96

Something went wrong. Please try again later.